Wilmer Cutler Pickering Hale and Dorr has advised Thermo Fisher. Mayo Clinic has announced the formation of Precure, LLC in partnership with Thermo Fisher Scientific. This...
Mayo Clinic and Thermo Fisher Scientific Form Precure, LLC to Drive Biomedical Data Innovation
Schrödinger Forms Tectora Therapeutics and Secures $55 Million Series A Investment
Wilmer Cutler Pickering Hale and Dorr and Ice Miller have advised Schrödinger. Schrödinger, Inc. has announced the formation of Tectora Therapeutics, a newly established biotechnology company,...
Biogen to Acquire RayThera for Up to $1 Billion
Wilmer Cutler Pickering Hale and Dorr has advised Biogen. Biogen Inc. (Nasdaq: BIIB) announced that it has entered into a definitive agreement to acquire RayThera Inc.,...
Otsuka’s Collaboration with ShapeTX
Latham & Watkins advised ShapeTX on the deal. Otsuka Pharmaceutical Co., Ltd. and ShapeTX announced a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
Sonoma Biotherapeutics’ Collaboration Agreement with Regeneron Pharmaceuticals
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
CytomX’s Research Collaboration With Moderna
Latham & Watkins LLP advised CytomX in the transaction. CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna,...
Erasca’s License Agreement With Novartis
Latham & Watkins advised Erasca on the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
CytomX’s Collaboration and Licensing Agreement With Regeneron Pharmaceuticals
Latham & Watkins LLP represented CytomX in the transaction. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) have announced a collaboration and licensing...
Merck’s $1.35 Billion Acquisition of Imago BioSciences, Inc.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...